Expiration date: 05/2026
PHARMACODYNAMICS
Chondroitin sulfate — the main component of proteoglycans, constituting together with the collagen fibers of the cartilage matrix. Artradol has chondroprotective properties. Inhibits activity of enzymes that cause degradation of the articular cartilage. Stimulates the production of proteoglycans by chondrocytes. Enhances the metabolic processes in the cartilage and subchondral bone. Influences calcium and phosphorus metabolism in the cartilage tissue.
The drug has anti-inflammatory and analgesic properties that helps reduce the release into synovial fluid mediators of inflammation and pain factors through synoviocytes and macrophages of the synovial membrane, inhibits the secretion of leukotriene B 4 and prostaglandin E 2 .
The drug helps to restore cartilage surfaces of joints, prevents the collapse of connective tissue. Normalizes the production of synovial fluid leading to improved joint mobility and reduce pain . Having structural similarity with heparin, Artradol can prevent the formation of fibrin clots in synovial and subchondral microcirculatory bed.
PHARMACOKINETICS
Chondroitin sulfate is readily absorbed when administered intramuscularly, 30 minutes has been found in high concentrations in the blood after 15 minutes in the synovial fluid. The maximum concentration is reached 1 hour after administration, then the drug concentration slowly decreases within 2 days. The drug accumulates mainly in cartilaginous tissue. The maximum concentration in articular cartilage is achieved in 48 hours. Excreted by the kidneys within 24 h.
INDICATIONS FOR USE
ARTRADOL — drug for the treatment of degenerative-distroficescimi diseases of joints and spine: primary arthrosis icny , osteoarthritis defeat major x Soest avow , intervertebral OST hondros.
CONTRAINDICATIONS
Hypersensitivity, children's age (the efficacy and safety of not installed).
Be wary of bleeding, the propensity to bleeding, thrombophlebitis. As well as during pregnancy and lactation.
RELEASE FORM
Lyophilisate for preparation of solution for intramuscular injection. 100 mg per ampoule with a capacity of 2 ml. of 10 vials in a cardboard holder, 5 ampoules in a plastic tray. 1 cardboard holder or 2 plastic tray with leaflet in a carton pack.
METHOD OF APPLICATION AND DOSES
Intramuscularly to 0.1 g a day. Before use, the contents of the vial are dissolved in 1 ml of water for injection. With good endurance dose increase to 0.2 g, since the 4th injection. The course of treatment 25-35 injection. Second course – 6 months. Duration of repeated courses of treatment is a doctor.
SIDE EFFECTS
Allergic reactions, hemorrhage at the injection site.
INTERACTION WITH OTHER DRUGS
May increase the action of indirect anticoagulants, antiplatelet agents, fibrinolitikov, which requires more frequent monitoring of blood clotting when used together.
STORAGE CONDITIONS
In a dry, protected from light place, at temperatures not above 20ºC.
Keep out of reach of children.
